Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MAX-10181 combined with lenvatinib in advanced malignant solid tumors
CTR20260715Phase 2Active
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MAX-10181, lenvatinib in Nonhematologic neoplasms, sponsored by Guangzhou Zaiji Medical Technology. Started Sep 2026; status: active.
02
Drugs
MAX-10181lenvatinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20260715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260715.